IPData Lab - Data collections: Standard Essential Patent

Comprehensive data for declared Standard-Essential Patents

Though SSOs do not conduct any verification to check if a declared patent is standard-essential or not, declared SEPs are the only comprehensive source for patents relating to a particular technology standard. IPDatalabs has retrieved all SEP declarations from major SSOs like ETSI, IEEE, ISO, CCSA, OMA, IMT, OneM2M, TIA, ATIS, ITU-T, ITU-R, IEC, IETF, ANSI and TTA, to provide a dashboard for easy searching and visualization of patents. In the next version we will also include declarations ARIB, CATV, UHDTV satellite and cable broadcasting, MPEG, HEVC and more.

The information declared by different SSOs is provided in different, which could be submitted as handwritten forms, scanned PDFs, or uploaded disclosures on the SSO database. Also, the patents declared by the applicants are not provided in a standardized format, which makes searching for patents very challenging.

Automated retrieval of patent numbers from PDFs or forms could produce errors. Therefore, our team extracted list of all SEPs from the above-mentioned sources and manually standardized patent application and publication numbers, to retrieve bibliographic and patent family details (patents filed in different countries). Since all patents in the family relate to the same invention, duplicate declarations were removed using the patent family data. We also conducted quality checks to compare if patent assignee matches that of the declaring party. In cases where the declaring company did not match the patent assignee, we manually checked and updated the patent and removed those patents, which did not seem to be relevant to the standard.

All SEPs reference a specific version of a standard, or a standard without specifying the version, or standardization projects in different standards (such as LTE). Only some SEPs declare precise standard sections or chapters.

Our dashboard provides the ability to search across all declared SEPs, and understand distribution of SEPs by ownership, SSOs, and other bibliographic characteristics.

Most patents are declared at ETSI (European Telecommunications Standards Institute) and the dashboard provides specific insights into SEP distribution across declared patents in 5G, 4G and 3G technologies.

Data Overview

Application Number	The number assigned by FDA staff to each Biologics License Application (BLA) for approval to market a biological product in the United States.
Product	The trademark or brand or proprietary name.
Applicant	The manufacturer or company that submits an application to FDA for approval of a drug, including a biological product, in the United States.
Active Ingredient	The nonproprietary name designated by FDA in the license for a biological product licensed under the PHS Act. The nonproprietary name means a name unprotected by trademark rights that is in the public domain.
Type	Either 351(a), 351(k) biosimilar, or 351(k) interchangeable
Strength	The amount of active ingredients in the dosage form of a drug
Dosage Form	The physical form that delivers a dose of the drug, such as a tablet, a capsule, or an injection.
Route of Administration	A way of administering a drug to a site in a patient (for example, intravenous or subcutaneous).
Product Presentation	The form of a drug that is presented by the manufacturer, e.g., Single-Dose Vial, Autoinjector, Pre-Filled Syringe, Pouch.
Status	Status indicates how a biological product is sold in the United States: Prescription (Rx), Over the Counter (OTC), Discontinued (Disc).
Licensure	Status of the product license, e.g., whether the product is currently licensed or whether the license has been revoked.
Approval Date	The date FDA approved the application or supplement.
Ref. Product Active Ingredient	The active ingredient of the single biological product, licensed (approved) by FDA under section 351(a) of the PHS Act, against which a proposed biosimilar or interchangeable product is compared.
Ref. Product	A reference product is the single biological product, licensed (approved) by FDA under section 351(a) of the PHS Act, against which a proposed biosimilar or interchangeable product is compared.
Submission Type	The type of submission, for example, the original application or a supplemental application.
Submission	Document number of the submission, e.g., Orig-1, Suppl-3
Supplement Number	Manufacturers may submit supplements to request approval for a change to an approved BLA. A number is assigned to each supplement which is usually, but not always, sequential, starting with 001.
License Number	The number of the license granted to the manufacturer by the FDA.
Product Number	A product number is assigned to each biological product associated with a BLA (Biologics License Application). For example, if the biological product is available in multiple strengths, there are multiple product numbers.
Center	Refers to either FDA's Center for Biologics Evaluation and Research (CBER) or Center for Drug Evaluation and Research (CDER).
Patent number	A list of all patents identified for a drug.
Ref. Product Exclusivity Expiration Date	The date on which the 12-year period of reference product exclusivity expires, including any applicable pediatric extension.

Date of First Licensure	The date on which any applicable reference product exclusivity begins to run. FDA has not made a determination of first licensure for each 351(a) biological product included in the Purple Book. The absence of a date of first licensure in the Purple Book does not mean that a biological product on the list is not, or was not, eligible for the periods of exclusivity described in section 351(k)(7) of the PHS Act.
Exclusivity Date	The date on which all applicable periods of exclusivity expire.
First Interchangeable Exclusivity Expiration Date	The date a first interchangeable product’s period of exclusivity ends.
Orphan Exclusivity Expiration Date	The latest date on which a period of seven-year period of orphan exclusivity expires, including any applicable pediatric extension.
Related applciations	The Continuation, Divisional, and CIP applications of the patents identified for a drug.
Target	A drug target is a molecule in the body, usually a protein, that is intrinsically associated with a particular disease process and that could be addressed by a drug to produce a desired therapeutic effect.
Indication	An indication of a drug refers to the use of that drug for treating a particular disease. All indications approved by FDA on a drug are listed.
Indication-Approval Date mapping	Map the Approval Date to each new indication on the same drug in a table view.
PTA	Patent Term Adjustment (PTA), which compensate for delays caused by USPTO during prosecution.
Requested PTE	The number of days requested for Patent Term Extension (PTE) by patentee on the patent related to a drug under 35 U.S.C. §156.
Granted PTE	The number of days indicated in the Patent Term Extension Certificate on the patent related to a drug.
Expiry date	The expiry date of an idenfied patent, taken into account of all relevant factors including PTA, PTE, terminal disclaimer, etc.
Relevant claims	The claim # of a patent that is specifically relevant to an approved drug.
Claim chart	Map the claims of a patent to a drug in a table view, explaning why the claims read on the drug.
Terminal disclaimer reference to	The patents referenced in a Terminal Disclaimer document, which disclaimed the term of the present patent beyond these referenced patents.
Terminal disclaimer reference by	The present patent that disclaimed the term beyond the referenced patents.
Bulk download Label PDF	Allow for bulk downloading drug Label PDF documents for the original approval and additional indications of a drug.
Bulk download PTE_related PDF	Allow for bulk downloading Patent Term Extension (PTE) related file history documents. Such documents include PTE application, the correspondence between USPTO and FDA, Notice of Final Determination, Election amongs multiple applicable patents, PTE Certificate, etc.

Two easy access options:

Online Search Access

This option is for customers that desire to immediately search and interact with this data set in an online research platform hosted by us, IPDataLab.

Select this option for electronic payment support leading to immediate access to the IPDataLab research platform.

Subscribe Now

Backfile and Updates

This option is for customers that desire to integrate some or all of this data set into their own commercial or research system. In most cases, redistribution of the data, even commercially, is not prohibited.

Select this option to access a contact form and send us a request for pricing.

Contact for pricing.

Standard Essential Patents

Gain powerful insights on SEP ownership to understand competitive environment

627

250+

40+

Comprehensive data for declared Standard-Essential Patents

Data Overview

Two easy access options:

Online Search Access

Backfile and Updates

Let’s start a conversation.